Ozmosi | BPX-601 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

BPX-601

Alternative Names: bpx-601, bpx601, bpx 601
Clinical Status: Inactive
Latest Update: 2023-04-20
Latest Update Note: Clinical Trial Update

Product Description

BPX-601, the companyÕs first GoCAR-T¨Êproduct candidate, incorporates iMC, BellicumÕs inducible co-activation domain.ÊBPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA). (Sourced from: https://ir.bellicum.com/news-releases/news-release-details/bellicum-reports-fda-lifted-clinical-hold-bpx-601-phase-12)

Mechanisms of Action: CAR-T, PSCA

Novel Mechanism: Yes

Modality: CAR-T (Unknown Type)

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bellicum
Company Location: HOUSTON TX 77098
Company CEO: Richard A. Fair
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Prostate Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT02744287

BP-012

P2

Suspended

Prostate Cancer

2025-10-01

19%

2023-04-22

Primary Endpoints|Treatments|Trial Status